CJC-1295 + GHK-Cu Stack: Complete Protocol, Dosing, and Evidence

What CJC-1295 and GHK-Cu Actually Do

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds GHRH receptors in the anterior pituitary and amplifies the natural GH pulse. The version without the drug affinity complex (sold as Modified GRF 1-29 or Mod GRF 1-29) has a half-life of roughly 30 minutes, generating a sharp, physiologic-style pulse. The DAC version extends half-life to approximately 6 to 8 days by covalently binding plasma albumin, producing a sustained GH elevation rather than discrete pulses. Teichman et al., JCEM 2006 confirmed dose-dependent IGF-1 increases with CJC-1295 DAC in a 52-subject RCT, with IGF-1 rising 28 to 39% above baseline at doses of 30 to 60 mcg/kg.

GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine bound to copper(II). It occurs naturally in human plasma, saliva, and urine at concentrations that decline from roughly 200 ng/mL at age 20 to under 80 ng/mL by age 60. Externally applied or injected GHK-Cu activates a broad gene-expression program. A landmark gene-array study by Pickart et al. Found GHK-Cu modulated over 4,000 human genes, with strong upregulation of collagen, elastin, and antioxidant pathways including superoxide dismutase and catalase. Pickart & Margolina, Symmetry 2018 remains the primary reference for this breadth of gene-level activity.

Why Combining Them Makes Biological Sense

The two peptides operate through entirely separate receptor systems. CJC-1295 works centrally via hypothalamic-pituitary signaling. GHK-Cu works peripherally, primarily at fibroblasts, keratinocytes, and wound-healing tissue. No competitive receptor interaction has been identified in published literature, and no pharmacokinetic interference has been described in animal models.

Elevated IGF-1 from CJC-1295 stimulates fibroblast proliferation. GHK-Cu supplies the downstream collagen and extracellular matrix machinery for those fibroblasts to act on. This sequential logic, GH axis priming followed by local tissue remodeling support, is the core rationale practitioners cite for combining them, even though no clinical trial has tested whether the combination produces additive or synergistic tissue outcomes.

Evidence Quality: What You Can and Cannot Conclude

Before moving to dosing, it is necessary to state the evidence ceiling clearly. CJC-1295 alone has two published human trials (Teichman 2006, Ionescu & Frohman 2006). GHK-Cu has human trials in wound healing, hair loss, and skin aging, but none using systemic subcutaneous injection in healthy adults at doses typically discussed in peptide communities. No published trial has tested this stack. Every dosing recommendation in this article is extrapolated from individual-compound studies, animal research, and structured practitioner-reported outcomes. Pickart, J Biomater Sci Polym Ed, 2008 notes that GHK-Cu's systemic safety profile in humans beyond topical application remains under-characterized.

CJC-1295 Mechanism and Pharmacology

DAC vs. No-DAC: A Clinically Meaningful Difference

The DAC modification attaches a lysine-maleimide moiety to the peptide chain, allowing it to bind plasma albumin reversibly. This extends the half-life from ~30 minutes (Mod GRF 1-29) to approximately 6 to 8 days. Teichman et al., JCEM 2006 showed that a single 60 mcg/kg dose of CJC-1295 DAC sustained GH elevation for more than 14 days post-injection in healthy adults aged 21 to 61.

Mod GRF 1-29 (no DAC) mimics the natural pulsatile pattern more closely, producing a sharp GH rise within 15 to 30 minutes of injection that returns to baseline within 2 hours. Practitioners who prioritize physiologic GH rhythmicity generally prefer Mod GRF 1-29, often combined with a GHRP such as ipamorelin to amplify the pulse. When stacking with GHK-Cu, either form of CJC-1295 is compatible; the choice depends on the practitioner's GH-pulse philosophy and patient compliance burden.

IGF-1 as the Monitoring Anchor

CJC-1295's clinical effect is tracked through serum IGF-1, not direct GH measurement (GH is pulsatile and a single draw is rarely informative). In the Teichman 2006 trial, mean IGF-1 SD scores increased from baseline by 28% at 30 mcg/kg and 39% at 60 mcg/kg. The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency defines the upper reference limit for IGF-1 SD score as +2; exceeding this threshold during peptide therapy should prompt dose reduction or cessation. Endocrine Society GH Deficiency Guideline, 2019.

Elevated IGF-1 carries theoretical oncologic risk. The COSMIC cohort (N=22,185) found IGF-1 levels in the highest quartile associated with a hazard ratio of 1.28 for colorectal cancer and 1.44 for premenopausal breast cancer vs. The lowest quartile. Renehan et al., Lancet 2004. This association does not establish causation from exogenous peptide use, but it argues strongly for keeping IGF-1 within normal reference range during any CJC-1295 protocol.

GHK-Cu Mechanism and Evidence Base

Collagen, Wound Healing, and Hair

GHK-Cu's best-characterized human evidence is in skin and wound applications. A double-blind trial (N=67) published in the Journal of Wound Care found that GHK-Cu-impregnated wound dressings reduced healing time of split-thickness graft donor sites by approximately 2 days vs. Standard saline dressings, with statistically significant differences in re-epithelialization at day 7. Mulder et al., 1994, as cited in Pickart 2008.

In hair loss, a randomized trial of 67 subjects comparing a GHK-Cu-containing topical solution to placebo found a 121% increase in hair follicle density versus a 7% increase in the placebo arm after 6 months of daily application. Amin & Bhaskaran, J Clin Aesthet Dermatol 2017.

Antioxidant and Anti-Inflammatory Gene Activation

GHK-Cu upregulates antioxidant enzymes including superoxide dismutase 1 (SOD1) and catalase. In an in vitro model using human fibroblasts, GHK-Cu at 1 nanomolar concentration increased SOD1 mRNA expression by 2.4-fold within 24 hours. Pickart & Margolina, Symmetry 2018. Downregulation of pro-inflammatory genes including TNF-alpha and interleukin-6 pathways has been shown in cell culture. Extrapolating these concentrations to in vivo systemic dosing in humans remains speculative without pharmacokinetic modeling for subcutaneous injection routes.

Copper Considerations

GHK-Cu is not simply GHK peptide, copper is a co-active component and an essential mineral with a narrow therapeutic window. The tolerable upper intake level for copper in adults is 10 mg/day per the NIH Office of Dietary Supplements. NIH ODS Copper Fact Sheet. At the peptide doses typically discussed (1 to 2 mg GHK-Cu per injection, with a molecular weight of approximately 340 g/mol for the copper salt), systemic copper delivery is well below this threshold for short-term use. Practitioners running protocols beyond 12 weeks should consider a serum ceruloplasmin and copper check to exclude accumulation.

Complete Stack Protocol

The following protocol synthesizes compound-specific human trial data, animal evidence, and structured practitioner-reported outcomes. No RCT has validated this exact combination. It should be implemented only under physician supervision with baseline and follow-up laboratory monitoring.

Phase 1: Baseline Assessment (Weeks 0)

Before the first injection, obtain:

• Serum IGF-1 (ng/mL, with age-adjusted reference range)
• Fasting glucose and hemoglobin A1c (CJC-1295 may reduce insulin sensitivity at supraphysiologic IGF-1 levels)
• CBC with differential
• Comprehensive metabolic panel
• Serum copper and ceruloplasmin (baseline only required if patient has prior copper-related history)
• For males over 40: PSA, as IGF-1 elevation has a theoretical prostate cell-growth association

The FDA's import alert 66-41 covers many compounded peptides, and patients should obtain peptides only through licensed compounding pharmacies verified by their prescribing physician. Patients purchasing peptides outside this channel cannot confirm purity, sterility, or concentration.

Phase 2: Induction (Weeks 1 to 4)

CJC-1295 (Mod GRF 1-29, no DAC):

• Dose: 100 mcg subcutaneous per injection
• Frequency: 3 injections per week, administered at bedtime to align with endogenous GH pulse
• Route: subcutaneous, abdomen or thigh, rotating sites
• Reconstitution: bacteriostatic water, typically 2 mL per 2 mg vial yields 1,000 mcg/mL; draw 0.1 mL per 100 mcg dose

If CJC-1295 DAC is chosen instead:

• Dose: 1 to 2 mg subcutaneous once weekly
• The Teichman 2006 trial used 30 to 60 mcg/kg; for a 75 kg adult that equates to 2.25 to 4.5 mg per injection. Practitioner-reported use tends to be lower (1 to 2 mg) to stay within tolerable IGF-1 SD score thresholds.

GHK-Cu:

• Dose: 1 mg subcutaneous per injection (induction)
• Frequency: 3 injections per week, same days as CJC-1295 Mod GRF 1-29; injected at a separate site, minimum 2 cm from CJC-1295 injection
• Timing: morning (separating from CJC-1295's bedtime dosing avoids any theoretical co-injection interaction at the same site)
• Topical option: For patients focused on skin or hair outcomes, 2 to 5% GHK-Cu topical solution applied once daily may be substituted or added without affecting systemic peptide pharmacokinetics

Phase 3: Maintenance (Weeks 5 to 12)

After IGF-1 is confirmed within normal range at the week-4 check:

• CJC-1295 Mod GRF 1-29: escalate to 200 mcg per injection if IGF-1 SD score is below +1.0 at week 4
• GHK-Cu: escalate to 2 mg per injection if week-4 tolerability is confirmed (no injection-site granuloma, no signs of copper excess)
• Frequency remains 3x weekly for both

IGF-1 should be re-checked at week 8. The Endocrine Society guideline language states: "IGF-1 levels should be maintained within the age- and sex-adjusted normal range during GH-stimulating therapy." Endocrine Society, JCEM 2019.

Phase 4: Cycle Break (Week 13 onward)

Neither compound has established long-term safety data beyond 3 to 6 months of continuous use. Standard peptide-community practice (not RCT-validated) involves a 4 to 8 week off-cycle period after every 12 weeks on. During the break, IGF-1 typically returns to pre-protocol baseline within 3 to 4 weeks for Mod GRF 1-29 users, given the peptide's short half-life. DAC users may see persistent IGF-1 elevation for 3 to 6 weeks after final injection due to the albumin-binding mechanism.

Injection Technique and Reconstitution

Reconstitution Steps

Lyophilized peptides require reconstitution with bacteriostatic water (BAC water contains 0.9% benzyl alcohol as a preservative). Add BAC water slowly, injecting it down the side of the vial rather than directly onto the peptide cake to avoid denaturing the protein structure. Swirl gently; do not vortex. A 2 mg vial reconstituted with 2 mL BAC water yields 1,000 mcg/mL for CJC-1295, and a 5 mg GHK-Cu vial with 5 mL yields 1,000 mcg/mL. Reconstituted peptides stored at 2 to 8°C (standard refrigerator temperature) retain stability for 28 to 30 days per standard compounding pharmacy guidance.

Injection Sites and Rotation

Subcutaneous injections target the fatty layer beneath the skin. Pinch the skin, insert a 29 to 31 gauge, 0.5-inch needle at a 45-degree angle, and inject slowly. Rotate among four quadrants of the abdomen (upper left, upper right, lower left, lower right) and optionally the outer thighs. Consistent same-site injections increase the risk of lipodystrophy. FDA MedWatch guidance on injection-site lipodystrophy is noted for insulin analogues but the anatomic mechanism applies broadly to subcutaneous peptide delivery.

Side Effects and Safety Signals

CJC-1295 Side Effects

Reported adverse effects in the Teichman 2006 trial (N=52) included:

• Flushing at injection time (18% of subjects, transient, less than 30 minutes)
• Injection-site reactions (redness, swelling) in 8% of subjects
• Headache (8%)
• No serious adverse events were reported at doses up to 60 mcg/kg

Supraphysiologic IGF-1 elevation is the primary safety concern for extended use. Fluid retention, carpal tunnel symptoms, and mild arthralgias mirror the side-effect profile of exogenous recombinant GH therapy at elevated doses. Consensus statement, GH Research Society, JCEM 2010 notes that GH-related adverse effects are dose-dependent and largely reversible with dose reduction.

GHK-Cu Side Effects

Topical GHK-Cu has a long safety record in cosmetic formulations at 0.1 to 5% concentration. Systemic subcutaneous injection data in humans are sparse. Animal data suggest good short-term tolerability; a rat study using 50 mg/kg intraperitoneal GHK-Cu showed no hepatotoxicity or renal toxicity at 14 days. Pickart 2008, J Biomater Sci Polym Ed. The main human-relevant concern is copper accumulation over extended injection protocols; monitoring serum ceruloplasmin every 12 weeks in chronic users is a reasonable precaution.

Drug Interactions

CJC-1295 may attenuate insulin sensitivity through IGF-1-mediated feedback. Patients on insulin, sulfonylureas, or other hypoglycemic agents need closer glucose monitoring. ADA Standards of Medical Care in Diabetes 2024 recommends HbA1c monitoring every 3 months in patients with any newly introduced agent that modulates insulin-like signaling.

No known direct pharmacokinetic interaction exists between CJC-1295 and GHK-Cu in published literature as of July 2025.

Who Should Not Use This Stack

Absolute contraindications (based on CJC-1295's GH-axis stimulation and GHK-Cu's proliferative tissue activity):

• Active or prior hormone-sensitive malignancy (breast, prostate, colorectal with IGF-1 receptor expression)
• Active acromegaly or pituitary adenoma
• Uncontrolled diabetes mellitus (fasting glucose above 200 mg/dL)
• Pregnancy or breastfeeding (no safety data)
• Pediatric patients (open growth plates; exogenous GHRH stimulation contraindicated)
• Wilson's disease or other copper metabolism disorders (GHK-Cu contraindicated)

Relative caution applies to patients with a first-degree family history of hormone-sensitive cancers, those on immunosuppressant therapy (GHK-Cu's immune-modulating gene effects are incompletely characterized in immunocompromised states), and patients with chronic kidney disease stage 3 or higher (altered copper and peptide clearance). KDIGO CKD Guideline 2024 does not address peptide use but provides the framework for renal dosing caution.

Monitoring Schedule

| Timepoint | Tests Required | |-----------|---------------| | Baseline (Week 0) | IGF-1, HbA1c, fasting glucose, CBC, CMP, serum copper, ceruloplasmin | | Week 4 | IGF-1, fasting glucose | | Week 8 | IGF-1, HbA1c, fasting glucose, CBC, CMP | | Week 12 (end of cycle) | Full panel as baseline | | Off-cycle (Week 16) | IGF-1 to confirm return to pre-protocol baseline |

Any IGF-1 SD score exceeding +2.0 at any timepoint is an indication to reduce CJC-1295 dose by 50% and recheck in 4 weeks. If still above +2.0, the CJC-1295 component should be discontinued for the remainder of the cycle. Endocrine Society GH Deficiency Guideline 2019 provides the IGF-1 SD score reference framework.

Regulatory Status

Neither CJC-1295 nor GHK-Cu holds FDA approval for the indications discussed in this article. CJC-1295 is not an FDA-approved drug. GHK-Cu is used in FDA-regulated cosmetic topical formulations but is not approved as an injectable therapeutic. Compounded versions of both peptides fall under 503A or 503B compounding pharmacy oversight. The FDA issued guidance in 2023 identifying several peptides as "essentially a copy" of approved drugs, which affects compounding eligibility. Patients should confirm current compounding status with their prescribing physician and pharmacy before initiating any protocol. FDA Drug Compounding Guidance, 2023.